

Application No.: 09/847,945
Filing Date: May 2, 2001
Response to Office Action mailed 05/19/2003
Page 3 of 10

Attorney Docket No.: ABI1460-3
(071243-1317)

Listing of Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

1. (Original) A method for treating hyperplasia in a subject in need thereof, said method comprising administering to said subject an effective amount of a composition comprising drug coated with a protein.
2. (Original). A method according to claim 1 wherein said drug is in nanoparticle form and is dispersed in said protein.
3. (Original) A method according to claim 1 wherein said hyperplasia occurs in blood vessel neointima.
4. (Original) A method according to claim 1 wherein said effective amount falls in the range of about 0.01 mg/kg up to about 15 mg/kg for a human subject.
5. (Original) A method according to claim 4 wherein said administration of said composition is repeated over a dosing cycle between 1 day and 6 months.
6. (Original) A method according to claim 1 wherein said composition is administered systemically.
7. (Original) A method according to claim 6 wherein administration is accomplished intra-arterially, intravenously, by inhalation, or orally.
8. (Original) A method according to claim 1 wherein said composition is administered before, during or after the occurrence of said hyperplasia.

Application No.: 09/847,945
Filing Date: May 2, 2001
Response to Office Action mailed 05/19/2003
Page 4 of 10

Attorney Docket No.: ABI1460-3
(071243-1317)

9. (Original) A method for reducing neointimal hyperplasia associated with vascular interventional procedure(s) in a subject in need thereof, said method comprising administering to said subject an effective amount of a composition comprising at least one drug coated with a protein.

10. (Original) A method according to claim 9 wherein said procedure comprises angioplasty, stenting or atherectomy.

11. (Original) A method according to claim 9 wherein said composition is administered before, during or after the vascular interventional procedure.

12. (Original) A method according to claim 9 wherein said composition is administered at the time of the vascular interventional procedure.

13. (Original) A method according to claim 9 wherein said effective amount falls in the range of about 0.01 mg/kg up to about 15 mg/kg for a human subject.

14. (Original) A method according to claim 13 wherein said administration of said composition is repeated over a dosing cycle between 1 day and 6 months.

15. (Original) A method according to claim 9 wherein said composition is administered systemically.

16. (Original) A method according to claim 9 wherein said composition is administered by deployment of a stent containing said at least one drug coated thereon.

17. (Original) A method to reduce proliferation and cell migration in a subject undergoing a vascular interventional procedure, said method comprising systemically administering a formulation comprising a drug that inhibits proliferation and cell migration, and

Application No.: 09/847,945
Filing Date: May 2, 2001
Response to Office Action mailed 05/19/2003
Page 5 of 10

Attorney Docket No.: ABI1460-3
(071243-1317)

a biocompatible protein to said subject before, during or after said procedure, wherein said drug is coated with said protein.

18. (Original). A composition for treatment of hyperplasia, said composition comprising at least one drug and protein.
19. (Original) A composition, according to claim 18 wherein said at least one drug is in nanoparticle form and is dispersed in said protein.
20. (Original) A composition according to claim 18 wherein said hyperplasia occurs in blood vessel neointima.
21. (Original) A composition according to claim 18 wherein said drug is a taxane or analog or homolog thereof, an epothilone or analog or homolog thereof, or a rapamycin or analog or homolog thereof.
22. (Original) A composition according to claim 21 wherein said taxane is paclitaxel.
23. (Original) A composition according to claim 18 wherein said composition is suitable for systemic administration.
24. (Original) A composition according to claim 23 wherein administration is accomplished intra-arterially, intravenously, by inhalation, or orally.
25. (Original) A composition for reducing neointimal hyperplasia associated with vascular interventional procedure(s), said composition comprising at least one drug coated with and a protein.

Application No.: 09/847,945
Filing Date: May 2, 2001
Response to Office Action mailed 05/19/2003
Page 6 of 10

Attorney Docket No.: ABI1460-3
(071243-1317)

26. (Original) A composition according to claim 25 wherein said procedure is angioplasty, stenting or atherectomy.

27. (Original) A composition according to claim 25 wherein said composition is suitable for systemic administration.

28. (Original) A composition according to claim 27 wherein administration is accomplished intra-arterially, intravenously, by inhalation, or orally.

29. (Original) A method to reduce the toxicity of a drug that inhibits proliferation and migration of cells, said method comprising combining said drug with a biocompatible protein, wherein said drug is coated with said protein.

30. (Original) A pharmaceutical formulation with reduced toxicity, said formulation comprising a drug that inhibits proliferation and cell migration, coated with a biocompatible protein.